National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
U19 AI171413
米国
引用
ジャーナル: Nat Commun / 年: 2025 タイトル: Cryo-EM structures of Nipah virus polymerases and high-throughput RdRp assay development enable anti-NiV drug discovery. 著者: Zhenhang Chen / Jeanne Quirit Dudley / Colin Deniston / Cosmo Z Buffalo / Debjani Patra / Dongdong Cao / Julia Hunt / Ahmed Rohaim / Debapriya Sengupta / Lan Wen / Tiffany Tsang / Lili Xie / ...著者: Zhenhang Chen / Jeanne Quirit Dudley / Colin Deniston / Cosmo Z Buffalo / Debjani Patra / Dongdong Cao / Julia Hunt / Ahmed Rohaim / Debapriya Sengupta / Lan Wen / Tiffany Tsang / Lili Xie / Michael DiDonato / Glen Spraggon / Matthew C Clifton / Nadine Jarrousse / Judith Straimer / Bo Liang / 要旨: Transcription and replication of the Nipah virus (NiV) are driven by the large protein (L) together with its essential co-factor phosphoprotein (P). L encodes all the viral enzymatic functions, ...Transcription and replication of the Nipah virus (NiV) are driven by the large protein (L) together with its essential co-factor phosphoprotein (P). L encodes all the viral enzymatic functions, including RNA-dependent RNA polymerase (RdRp) activity, while the tetrameric P is multi-modular. Here, we investigate the molecular mechanism of the NiV polymerase and build tools for anti-NiV drug discovery. We analyze and compare multiple cryo-EM structures of both full-length and truncated NiV polymerases from the Malaysia and Bangladesh strains. We identify two conserved loops in the polyribonucleotidyltransferase (PRNTase) domain of L and the binding between RdRp-PRNTase and CD domains. To further assess the mechanism of NiV polymerase activity, we establish a highly sensitive radioactive-labeled RNA synthesis assay and identify a back-priming activity in the NiV polymerase as well as a fluorescence and luminescent-based non-radioactive polymerase assay to enable high-throughput screening for L protein inhibitors. The combination of structural analysis and the development of both high-sensitive and high-throughput biochemical assays will enable the identification of new direct-acting antiviral candidates for treating highly pathogenic henipaviruses.